AgeX Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to pioneering and commercializing groundbreaking therapies that address human aging and degenerative conditions. The company's developmental pipeline features several promising cell-based therapeutic candidates: AGEX-BAT1: A cell therapy designed to manage various age-related metabolic disorders, including adult-onset Type II diabetes and obesity. AGEX-VASC1: A cell-based approach aimed at re-establishing vital vascular support in aged ischemic tissues, which could be relevant for conditions such as peripheral vascular disease and ischemic heart disease. Beyond cell therapies, AgeX is also exploring other modalities: Its primary drug candidate in the discovery phase is AGEX-iTR1547, a drug formulation focused on achieving scarless wound repair. For induced tissue regeneration, its leading biologic candidate is AGEX-iTR1550, which leverages gene delivery technology. Furthermore, AgeX maintains a research collaboration with the University of California at Irvine, jointly working to develop cellular therapies for various neurological disorders. Founded in 2017, AgeX Therapeutics, Inc. maintains its headquarters in Alameda, California.